Document › Details

Medigene AG. (6/27/14). "Press Release: Medigene AG Plans Funding of Cancer Immunotherapy Programs by Issue of New Shares and Convertible Bonds [Not for release, publication or distribution in the United States, Canada, Japan or Australia]". Martinsried.

Organisations Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
  Organisation 2 SynCore Biotechnology Co., Ltd.
  Group Sinphar Pharmaceutical (Group)
Products Product T cell therapy
  Product 2 investment banking
Index terms Index term Medigene–SEVERAL: investment, 201406–201407 capital increase €15.9m 3m new shares + 818.7k convertible bonds
  Index term 2 Sinphar Pharmaceutical–Medigene: EndoTAG-1, 201305– collab expansion co-developm + commercialisation globally by SynCore Biotechnology
Person Person Llewellyn-Davies, Peter (Apeiron 201807– CEO before CFO+CBO before Accellerate Partners + Medigene + Wilex)
     


   
Record changed: 2019-06-09

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px

More documents for Medigene (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] – Putting Information into Context 600x60px




» top